摘要
目的比较国产与进口促性腺激素用于子宫内膜异位症(EMS)合并不孕妇女进行体外受精-胚胎移植(IVFET)助孕治疗的结局。方法回顾性分析2010年1月至2014年1月我所行IVF-ET助孕的EMS合并不孕患者。满足纳入标准的患者根据促性腺激素的来源分为A组(国产组,201例)与B组(进口组,880例)。比较两组患者的一般资料、控制性促排卵(COS)周期资料及移植周期临床助孕结局。结果 (1)A组患者较B组患者年龄更大(32.6±3.3vs.31.7±3.8)、不孕年限更长(6.6±3.9vs.6.0±3.6)、基础窦卵泡数更少(8.3±4.1vs.9.1±4.2),均有统计学差异(P<0.05);(2)两组患者周期取消率(11.9%vs.12.8%)以及因未获卵、无可移植胚胎、OHSS中重度等取消周期原因比较,均无统计学差异(P>0.05);(3)A组较B组促性腺激素(Gn)启动剂量(250.5±55.7Uvs.227.3±52.6U)及总量(2 626.4±804.6Uvs.2 432.2±750.4U)更大,卵泡数(9.3±4.7vs.10.1±5.0)、获卵数(8.3±5.0vs.9.3±5.1)、获成熟(MⅡ)卵数(6.9±4.4vs.8.0±4.8)、获卵率(88.7%vs.91.9%)、获MⅡ卵率(83.7%vs.85.9%)、可移植胚胎数(3.1±2.6vs.3.7±2.3)、优质胚胎数(1.0±0.8vs.1.3±1.1)更低,均有统计学差异(P<0.05);(4)Gn总费用比较,A组显著低于B组(5 258.4元vs.9 979.0元,P<0.05);(5)A、B组分别有177例、767例行胚胎移植,临床妊娠率(57.1%vs.64.9%)、种植率(40.3%vs.45.7%)、流产率(9.9%vs.12.0%)、活产率(49.2%vs.54.6%)及胎儿出生缺陷率(3.3%vs.2.5%)比较,均无统计学差异(P>0.05)。结论国产促性腺激素用于子宫内膜异位症(EMS)合并不孕妇女进行IVF-ET助孕治疗可获得与使用进口促性腺激素助孕相似的临床妊娠率、活产率及出生缺陷率,由于其费用明显降低,可作为EMS患者IVF助孕中更经济实惠的用药选择。
Objective： To compare the outcome of IVF-ET treated with domestic or imported gonadotropin in infertile patients with endometriosis. Methods： A retrospective analysis was performed in infertile endometriosis patients undergone IVF- ET in our center from January 2010 to January 2014. The patients fulfilled all the including criteria were divided into group A（domestic drug, 201 patients）and group B（imported drug, 880 patients）. The characteristics of patients, data of controlled ovarian stimulation cycles, and outcomes were compared between the two groups. Results： The patients in group A and B were significantly different in terms of age（32.6± 3.3 vs. 31.7±3.8） ,duration of infertility[（6.6±3.9）years vs. （6.0±3.6）years ]and basal ovarian antral follicle count（AFC）（8.3±4.1 vs. 9.1±4.2）（P〈0.05）. There was no signifieant difference in cycle cancel rate （11.9% vs. 12.8%）and cycle cancel reasons（P〉0.05）. The gonadotropin launch doses [（250. 5±55. 7） U vs. （227.3±52.6）U],total doses [（2 626.4±804.6）U vs. （2 432.22±750.4）U],follicle number（9.3±4.7 vs. 10.12±5.0）,retrieval oocyte number（8.32±5.0 vs. 9.3±5.1）,M Ⅱ oocyte number（6.9±4.4 vs. 8.0±4.8）,oocyteretrieval rate（88.7% vs. 91.9%）,retrieval maturate oocyte rate（83.7% vs. 85.9%）, transferable embryo number（3.1±2.6 vs. 3.7±2.3）,high quality embryo number（1.0±0.8 vs. 1.3± 1.1） were significantly different between the two groups （P 〈 0.05）. The total cost for gonadotropin in group A were significantly lower than that in group B（5 258.4 RMB vs. 9 979.0 RMB,P〈0.05）. There were 177 embryo transfer cycles in group A and 767 cycles in group B. There was no significant differences in the clinical pregnancy rate（57.1% vs. 64.9%）,implantation rate（40.3% vs. 45.7%）, abortion rate （9.9% vs. 12.0%）,livebirthrate（49.2% vs. 54.6%）andbirthdefectsrate（3.3% vs. 2.5%）betweenthe two groups（P〉0.05）.Conclusions. The clinical pregnancy with
出处
《生殖医学杂志》
CAS
2015年第11期879-884,共6页
Journal of Reproductive Medicine
基金
重庆市卫生计生委科研项目(2011-2-303)
